Primary Job Title Senior Vice President & Chief Medical Officer Primary Organization 
Illumina
Location San Francisco, California, United States Regions San Francisco Bay Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn
Richard Klausner joined Illumina in September 2013 as Senior Vice President and Chief Medical Officer. Richard is responsible for Illumina’s strategies for advancing genomics into clinical medicine and public health. He is also part of Illumina’s executive management team, which is responsible for directing all aspects of company strategy, planning
and operations.
Richard is a Scientific Advisor at Cyterix Pharmaceuticals Inc. He co-founded Pathwork Diagnostics, Inc. (Alternative name is Predicant Biosciences Inc.) in 2002.
He serves as the Managing Partner at The Column Group LLC. He served as the Chairman of the Strategic Development and Scientific Advisory Council at Sanofi from March 1, 2011 to January 2013.
Richard serves as the Chairman of the National Science Education Standards Projects of the National Academy of Science, overseeing the first comprehensive process to provide a vision of scientific literacy in the American educational system and the criteria required to achieve it.
He served as Co-Chairman of the Scientific Advisory Board and Scientific Advisor at Aragon Pharmaceuticals, Inc. He served as an Executive Director for Global Health at the Bill & Melinda Gates Foundation. Richard served as the President at the American Society of Clinical Investigation.
He served as an Advisor to the President of the Academies for counter-terrorism, and a Liaison to the White House Office of Science and Technology Policy. From 1979 to 1981, he worked at NIH in National Cancer Institute's (NCI) Laboratory of Mathematical Biology.
He served as a Director of Pathwork Diagnostics, Inc. and Immune Design Corp. He served as Director of 3-V Biosciences, Inc. He served as a Director of NCI from August 1, 1995 to 2001.
He serves as a Member of Scientific Advisory Board at NGM Biopharmaceuticals, Inc., Immune Design Corp., Constellation Pharmaceuticals and Audax Health Solutions. Richard served as a Distinguished Scientific and Strategic Advisor of Aveo Pharmaceuticals, Inc.
Richard currently sits on the board of Juno Therapeutics. He is also the Chief Strategy Advisor for USAID. He is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences.
He served as a Member of Scientific Advisory Board at Infinity Pharmaceuticals, Inc., Igenica, Inc. and T2 Biosystems, Inc.
Rick holds an M.D. from Duke Medical School.
